Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) EPS (Weighted Average and Diluted) (2021 - 2025)

Mirum Pharmaceuticals (MIRM) has 5 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.1 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 79.59% year-over-year to -$0.1; the TTM value through Dec 2025 reached -$0.47, up 74.59%, while the annual FY2025 figure was -$0.47, 74.59% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.1 in Q4 2025 per MIRM's latest filing, down from $0.05 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $1.91 in Q4 2021 and bottomed at -$1.94 in Q2 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.6, with a median of -$0.57 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): tumbled 151.83% in 2022, then skyrocketed 116.67% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $1.91 in 2021, then tumbled by 151.83% to -$0.99 in 2022, then surged by 30.3% to -$0.69 in 2023, then increased by 28.99% to -$0.49 in 2024, then surged by 79.59% to -$0.1 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.1 in Q4 2025, $0.05 in Q3 2025, and -$0.12 in Q2 2025.